Skip to main content
. 2009 Feb 6;113(24):6120–6127. doi: 10.1182/blood-2008-11-190421

Figure 1.

Figure 1

Bortezomib decreases proliferation and sensitizes RENCA tumor cells to syngeneic NK-cell lysis, but does not induce tumor apoptosis or alter cell-surface expression of MHC class I, DR5, Fas, Rae-1, or ICAM-1. RENCA or LLC1 tumor cells were treated with 20 nM bortezomib for 18 hours and were analyzed for (A) syngeneic BALB/c or C57BL/6 NK cell lysis in a 4-hour 51Cr release assay; (B) surface expression of MHC class I, Fas, DR5, Rae-1, Mult-1, H60, and ICAM-1 (x-axis shows log fluorescence); (C) proliferation (after 72 hours of bortezomib treatment [0.5-20 nM]);and (D) induction of apoptosis (assessed by staining for annexin V and propidium iodide). y- and x-axes show log fluorescence. Error bars in panels A and C depict SD.